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Letters 
Correspondance
Another approach to 
managing depression
e read the CME article "An approach to man­
aging depression”1 with great interest. Both 
in Canada and in the Netherlands, patients suffer­
ing from depression are most commonly treated by 
their family physicians.2,3 We agree with the authors 
that validated rating scales are very useful for assess­
ing the severity of depression, monitoring response 
to therapy, and determining remission of depressive 
symptoms. Family physicians, GP psychotherapists, 
and psychiatrists should probably use these scales 
more often.
We were disappointed that the article's main 
thrust seemed to be encouraging use of the HAM- 
D7 scale; in fact, in addition to a full-page repro­
duction of this scale, the HAM-D7 was mentioned 
14 times. We have attempted to use this scale in our 
family practices and have found it to be quite time­
consuming. It does not fit well into the flow of the 
normal 15-minute (or less) office visit. Although 
the criterion standard for diagnosis of depression in 
clinical practice remains a focused in-depth inter­
view by an experienced clinician, for busy family 
physicians, the ideal test is brief, accurate, easily 
completed by patients, and reliable for screening, 
diagnosis, and outcome assessment.
An excellent example of such a validated scale is 
the nine-item Patient Health Questionnaire (PHQ- 
9).4-8 Although copyrighted, the PHQ-9 is avail­
able as a free download and can be copied for use 
by clinicians. The PHQ-9 has been validated for 
screening, diagnosis, evaluation of severity, moni­
toring response to therapy, and determining remis­
sion. Adult patients with grade 4 English literacy 
skills can complete the form in less than 3 minutes. 
Clinicians can score it quickly and easily and can 
then use the answers to direct the course of the 
consultation. The sensitivity and specificity of the 
PHQ-9 compare favourably with a structured psy­
chiatric interview. Compared with the HAM-D7, 
the PHQ-9 is much faster and easier for physicians
to administer and is, therefore, more likely to be 
adopted in busy family practices.
Preliminary research on use of the PHQ-9 in a 
British Columbia family practice collaborative has 
confirmed excellent uptake by family physicians, 
with 70% of more than 2000 patients with depres­
sion completing at least one PHQ-9 in the first year 
of analysis (work in progress). The Guideline and 
Protocols Advisory Committee, jointly sponsored 
by the M inistry of Health Services and the BC 
Medical Association, has adopted the PHQ-9 as the 
preferred scale for following depression (see www. 
healthservices.gov.bc.ca/m sp/protoguides/gps/ 
depression.pdf). It is also in increasingly wide use 
in the United States. The PHQ 9 can be downloaded 
and copied free from h ttp ://w w w .depression- 
p rim arycare .o rg /c lin ic ians/too lk its/m ateria ls/ 
form s/phq9/questionnaire/.
Finally, one of the authors of the CME article 
is the originator of the HAM-D7 scale,9 and is 
the principal investigator of an industry-funded 
validation study of the HAM-D7 in primary care. 
We think this should have been mentioned in the 
"Competing interests” section.
—Michelle Greiver, m d , c c f p  
North York, Ont 
—Ellen Anderson, m d , m h s c  
Sooke, BC
—Evelyn van Weel-Baumgarten, m d , p h d  
Nijmegen, The Netherlands 
by e-mail
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Response
W e thank Drs Greiver, Anderson, and van Weel- Baumgarten for their interest and comments 
regarding the HAM-D7 scale.
The issue that they raise, as we understand it, 
is that the time required to administer the HAM- 
D7 is not compatible with the "normal 15-minute 
(or less) office visit.” They state that a diagnostic 
scale or symptom m easurem ent tool that could 
be administered in "less than 3 minutes” would be 
better accepted in busy family practices.
The experiences of Drs Greiver, Anderson, and 
van Weel-Baumgarten appear to diverge from those 
of many of their colleagues in primary and tertiary 
care settings across Canada.
The first author of the original HAM-D7 valida­
tion (R.S.M.) has personally observed (at Mainpro- 
C, provincial, and national primary care meetings) 
more than 500 primary care physicians from across 
Canada adm inister the HAM-D7. The time to 
administer the HAM-D7 has been approximately 
2 to 5 minutes. Our group has recently validated 
the HAM-D7 in 47 prim ary care centres across 
Canada. The primary care physicians in this ini­
tiative reported that the brevity of the scale was a 
great asset when compared with other scales.
We do not know why Dr Greiver and her col­
leagues find the scale "quite time-consuming.” The 
seven items contained in the HAM-D7 are the 
m ost frequently endorsed symptoms of depres­
sion, including depressed mood, anxiety, and sui­
cidal ideation. These depressive symptoms have 
high face validity and should be evaluated system­
atically in any depressed patient. The 
HAM-D7 is simply a mechanism 
for quantifying and objectifying the 
evaluation.
The authors mention and endorse 
use of the nine-item Patient Health 
Question (PHQ-9). The PHQ-9 is a 
self-administered scale, derived from 
a longer psychiatric diagnostic screen­
ing tool, the Primary Care Evaluation 
of Mental Disorders (PRIME-MD).
The PRIME-MD screens for five of the most com­
mon groups of psychiatric disorders in primary care: 
depression, anxiety, alcohol abuse, somatoform disor­
ders, and eating disorders.
Pfizer Inc holds the copyright to the PHQ-9. 
Pfizer is the manufacturer of sertraline (Zoloft). In 
Canada and the United States, sertraline is indi­
cated for depression and several anxiety disorders. 
Pfizer sales and m arketing departm ents heavily 
promoted the PRIME-MD across Canada to assist 
family physicians in diagnosing psychiatric disor­
ders, notably depression and anxiety.
N evertheless, we believe tha t the PHQ-9 is 
a well validated and very useful diagnostic and 
evaluation tool.1 To our knowledge, however, the 
PHQ-9 has not been validated in both prim ary 
and tertiary care settings, with a remission cutoff 
score that correlates with the HAM-D17 score of 
7 or less. The HAM-D17 score of 7 or less, albeit 
imperfect, is the m ost cited definition of rem is­
sion in depression.2
The original HAM-D7 validation (the scale 
reported in the Canadian Family Physician article3) 
was not supported by any pharmaceutical company. 
The HAM-D7 is the property of academia and is 
available free of charge to practitioners. Subsequent 
validation of the HAM-D7 in primary care was sup­
ported by Wyeth, the manufacturer of venlafaxine 
(Effexor). That disclosure will appear on all commu­
nications regarding this national primary care valida­
tion study, the results of which are yet to be reported.
We do agree with Dr Greiver and her colleagues 
that scales should be employed more frequently in 
clinical practice. The HAM-D7 is not a diagnostic 
scale. It is a symptom-measurement tool that can be 
administered quickly, is comprehen­
sive, has high face validity, and helps 
determine the effectiveness of anti­
depressant medication and whether 
remission has occurred. The HAM- 
D7 is currently the only brief depres­
sion scale with rem ission cutoff 
scores defined for primary and spe­
cialty health care settings that corre­
late with the most cited definition of 
remission in depression research.
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We hope the HAM-D7 will help sharpen the 
focus in the therapeutic environment and improve 
patien t outcom es. We also hope tha t further 
research will continue to refine critical end points 
in depression and how best to measure them.
—Roger S. McIntyre, m d , f r c p c  
Head, Mood Disorders 
Psychopharmacology Unit 
University Health Network 
—Jakub Z. Konarski, m s c  
Toronto, Ont 
by email
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New family practice 
residency program
W e thought your readers involved in teaching family practice residents might be interested 
in learning of a new program we have instituted.
St Paul's Hospital is a tertiary care 
teaching hospital with family prac­
tice as a full-admitting service. We 
have designated beds where patients 
are admitted from emergency and 
m anaged by the ir fam ily physi­
cians and first-year family practice 
residents. We believe that, in te r­
tiary care teaching hospitals, this is 
unique to the Ottawa program and 
our program.
The challenges of maintaining a family doctor 
presence in a tertiary care hospital are well known. 
In many tertiary care facilities many barriers exist 
for family physicians, not the least of which is the 
"culture.” A relative shortage of general internal 
medicine services in our facility has resulted in an 
opportunity to highlight the profile and value of 
family medicine.
As of October, we have started a new family prac­
tice consultation service for inpatient psychiatry. 
Approximately 100 patients pass through the psy­
chiatry inpatient beds each month. These patients 
often have medical problems that need address­
ing, and many do not have family physicians. Until 
now, the psychiatrists have consulted specialists 
for these problems. There were concerns, how­
ever, with timely access, follow up, and the need for 
many specialty consultations for one patient. We 
were asked to provide a regular consultation ser­
vice to the inpatients. This consists of daily visits by 
a second-year family practice resident and a fam­
ily physician to patients with problems. Problems 
range from liver disease, cellulitis and other derma- 
tologic conditions, minor fractures, and infections, 
to arthritic conditions, diabetes, and gynecological 
problems. The program has so far met with great 
enthusiasm from the psychiatry departm ent and 
the residents involved.
We intend to submit a program description with 
our evaluation data. In the meantime, if any other 
residency program wishes for additional informa­
tion, they can contact us directly.
—Dara Behroozi, m b  b s , c c f p  
—Garey Mazowita, m d , c c f p , f c f p  
Vancouver, BC 
by e-mail
Family practice 
websites
The recent article by Dr Michelle Greiver, "Practice Tips: Website 
for your family practice”1 provided 
an excellent overview of the topic.
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